Effect of glucuronidation on transport and tissue accumulation of tyrosine kinase inhibitors: consequences for the clinical management of sorafenib and regorafenib
暂无分享,去创建一个
F. Goldwasser | C. Tlemsani | R. Coriat | B. Blanchet | A. Thomas-Schoemann | P. Boudou-Rouquette | J. Durand | A. Cessot | J. Alexandre | O. Huillard | J. Arrondeau | J. Giroux
[1] P. MacEneaney,et al. Body Composition by Computed Tomography as a Predictor of Toxicity in Patients With Renal Cell Carcinoma Treated With Sunitinib , 2017, American journal of clinical oncology.
[2] Jaw-Yuan Wang,et al. FOLFIRI and regorafenib combination therapy with dose escalation of irinotecan as fourth-line treatment for patients with metastatic colon cancer according to UGT1A1 genotyping , 2014, OncoTargets and therapy.
[3] A. Paci,et al. Review of therapeutic drug monitoring of anticancer drugs part two--targeted therapies. , 2014, European journal of cancer.
[4] R. Paschke,et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial , 2014, The Lancet.
[5] A. Palazzo,et al. Incidence and relative risk of hepatic toxicity in patients treated with anti‐angiogenic tyrosine kinase inhibitors for malignancy , 2014, British journal of clinical pharmacology.
[6] A. Sparreboom,et al. Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro–in vivo correlations , 2014, British Journal of Cancer.
[7] Andrew Rowland,et al. The UDP-glucuronosyltransferases: their role in drug metabolism and detoxification. , 2013, The international journal of biochemistry & cell biology.
[8] K. Brouwer,et al. Sorafenib Hepatobiliary Disposition: Mechanisms of Hepatic Uptake and Disposition of Generated Metabolites , 2013, Drug Metabolism and Disposition.
[9] Y. Pithavala,et al. Clinical Pharmacology of Axitinib , 2013, Clinical Pharmacokinetics.
[10] Y. Fujiyama,et al. Pharmacokinetic interaction between sorafenib and prednisolone in a patient with hepatocellular carcinoma , 2013, Cancer Chemotherapy and Pharmacology.
[11] O. Mir,et al. Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients , 2013, British Journal of Cancer.
[12] S. Baker,et al. Contribution of OATP1B1 and OATP1B3 to the Disposition of Sorafenib and Sorafenib-Glucuronide , 2013, Clinical Cancer Research.
[13] H. Gurney,et al. Evidence for therapeutic drug monitoring of targeted anticancer therapies. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] O. Mir,et al. Saturable absorption of sorafenib in patients with solid tumors: a population model , 2012, Investigational New Drugs.
[15] O. Mir,et al. Sorafenib exposure decreases over time in patients with hepatocellular carcinoma , 2012, Investigational New Drugs.
[16] M. Loriot,et al. Early Sorafenib-Induced Toxicity Is Associated with Drug Exposure and UGTIA9 Genetic Polymorphism in Patients with Solid Tumors: A Preliminary Study , 2012, PloS one.
[17] O. Mir,et al. Sarcopenia Predicts Early Dose-Limiting Toxicities and Pharmacokinetics of Sorafenib in Patients with Hepatocellular Carcinoma , 2012, PloS one.
[18] Tingjun Hou,et al. New Use for an Old Drug: Inhibiting ABCG2 with Sorafenib , 2012, Molecular Cancer Therapeutics.
[19] Martin Büchert,et al. A Phase I Dose–Escalation Study of Regorafenib (BAY 73–4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors , 2012, Clinical Cancer Research.
[20] G. Giaccone,et al. Sorafenib Is an Inhibitor of UGT1A1 but Is Metabolized by UGT1A9: Implications of Genetic Variants on Pharmacokinetics and Hyperbilirubinemia , 2012, Clinical Cancer Research.
[21] O. Mir,et al. Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma , 2011, Investigational new drugs.
[22] U. Fuhr,et al. Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors , 2011, Clinical pharmacokinetics.
[23] O. Mir,et al. Functional and Clinical Evidence of the Influence of Sorafenib Binding to Albumin on Sorafenib Disposition in Adult Cancer Patients , 2011, Pharmaceutical Research.
[24] Uwe Fuhr,et al. Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors , 2011, Clinical pharmacokinetics.
[25] J. Schellens,et al. Moving towards dose individualization of tyrosine kinase inhibitors. , 2011, Cancer treatment reviews.
[26] G. Szakács,et al. Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: substrates, chemosensitizers or inducers of acquired multidrug resistance? , 2011, Expert opinion on drug metabolism & toxicology.
[27] R. Kerbel,et al. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis , 2011, Nature Reviews Clinical Oncology.
[28] Sagar Agarwal,et al. The Role of the Breast Cancer Resistance Protein (ABCG2) in the Distribution of Sorafenib to the Brain , 2011, Journal of Pharmacology and Experimental Therapeutics.
[29] E. Heath,et al. A Phase I Study of the Pharmacokinetic and Safety Profiles of Oral Pazopanib With a High‐Fat or Low‐Fat Meal in Patients With Advanced Solid Tumors , 2010, Clinical pharmacology and therapeutics.
[30] L. Birdsell,et al. Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[31] P. Casali,et al. Gastrointestinal stromal tumours : ESMO Clinical Practice Guidelines for diagnosis , treatment and follow-up , 2010 .
[32] Tae Won Kim,et al. Cross-sectional study of imatinib plasma trough levels in patients with advanced gastrointestinal stromal tumors: impact of gastrointestinal resection on exposure to imatinib. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] Jos H. Beijnen,et al. Breast Cancer Resistance Protein and P-glycoprotein Limit Sorafenib Brain Accumulation , 2010, Molecular Cancer Therapeutics.
[34] J. Magdalou,et al. Insights on membrane topology and structure/function of UDP-glucuronosyltransferases , 2010, Drug metabolism reviews.
[35] S. Baker,et al. Interaction of the Multikinase Inhibitors Sorafenib and Sunitinib with Solute Carriers and ATP-Binding Cassette Transporters , 2009, Clinical Cancer Research.
[36] Jos H Beijnen,et al. The biological and clinical role of drug transporters at the intestinal barrier. , 2009, Cancer treatment reviews.
[37] A. Stead,et al. Effects of food on the relative bioavailability of lapatinib in cancer patients. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] S. Paggi,et al. Sorafenib in Advanced Hepatocellular Carcinoma , 2008 .
[39] M. Ratain,et al. Pharmacogenetic Pathway Analysis of Irinotecan , 2008, Clinical pharmacology and therapeutics.
[40] Jeffrey W. Clark,et al. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. , 2007, The oncologist.
[41] Apurva A Desai,et al. Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.
[42] M. Radtke,et al. Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics , 2006, Cancer Chemotherapy and Pharmacology.
[43] John Smeraglia,et al. Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects , 2006, Anti-cancer drugs.
[44] D. Hirata,et al. Mutational analysis of the yeast multidrug resistance ABC transporter Pdr5p with altered drug specificity , 2005, Genes to cells : devoted to molecular & cellular mechanisms.
[45] Kathleen M Sakamoto. Su-11248 Sugen. , 2004, Current opinion in investigational drugs.
[46] S. Wilhelm,et al. BAY 43-9006: preclinical data. , 2002, Current pharmaceutical design.
[47] H. Hirte,et al. BAY 43-9006: early clinical data in patients with advanced solid malignancies. , 2002, Current pharmaceutical design.
[48] Nancy Woods,et al. Cancer and comorbidity , 2000, Cancer.
[49] A. Di Rienzo,et al. Phenotype‐genotype correlation of in vitro SN‐38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism , 1999, Clinical pharmacology and therapeutics.
[50] F. Goldwasser,et al. Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.
[51] M. Ratain,et al. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. , 1994, Cancer research.
[52] A. M. Hilliard. AFFILIATION , 1910 .
[53] F. Goldwasser,et al. Drug interactions with solid tumour-targeted therapies. , 2014, Critical reviews in oncology/hematology.
[54] N. Gray,et al. Targeting cancer with small molecule kinase inhibitors , 2009, Nature Reviews Cancer.
[55] Armando Santoro,et al. Sorafenib: a review of its use in advanced hepatocellular carcinoma. , 2009, Drugs.
[56] Peter Lloyd,et al. Clinical Pharmacokinetics of Imatinib , 2005, Clinical pharmacokinetics.
[57] P. Borst,et al. Mammalian ABC transporters in health and disease. , 2002, Annual review of biochemistry.